A common polymorphism acts as an intragenic modifier of mutant p53 behaviour (Q28118809)

4 January 2017

title

A common polymorphism acts as an intragenic modifier of mutant p53 behaviour (English)

1 reference

4 January 2017

M. C. Marin

1

1 reference

4 January 2017

C. A. Jost

2

1 reference

4 January 2017

L. A. Brooks

3

1 reference

4 January 2017

M. S. Irwin

4

1 reference

4 January 2017

J. O'Nions

5

1 reference

4 January 2017

J. A. Tidy

6

1 reference

4 January 2017

N. James

7

1 reference

4 January 2017

J. M. McGregor

8

1 reference

4 January 2017

C. A. Harwood

9

1 reference

4 January 2017

I. G. Yulug

10

1 reference

4 January 2017

K. H. Vousden

11

1 reference

4 January 2017

M. J. Allday

12

1 reference

4 January 2017

B. Gusterson

13

1 reference

4 January 2017

S. Ikawa

14

1 reference

4 January 2017

P. W. Hinds

15

1 reference

4 January 2017

T. Crook

16

1 reference

4 January 2017

W. G. Kaelin

17

1 reference

4 January 2017

language of work or name

English

0 references

publication date

1 May 2000

1 reference

4 January 2017

1 reference

4 January 2017

volume

25

1 reference

4 January 2017

issue

1

1 reference

4 January 2017

page(s)

47–54

1 reference

The emerging p53 gene family

4 January 2017

cites work

1 reference

7 January 2021

Mutually compensatory mutations during evolution of the tetramerization domain of tumor suppressor p53 lead to impaired hetero-oligomerization

1 reference

7 January 2021

Viral oncoproteins discriminate between p53 and the p53 homolog p73.

1 reference

7 January 2021

Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers

1 reference

7 January 2021

Two new p73 splice variants, gamma and delta, with different transcriptional activity.

1 reference

7 January 2021

p73 and p63 are homotetramers capable of weak heterotypic interactions with each other but not with p53

1 reference

7 January 2021

The spectrum of mutations at the p53 locus. Evidence for tissue-specific mutagenesis, selection of mutant alleles, and a "gain of function" phenotype

1 reference

7 January 2021

Molecular basis for heterogeneity of the human p53 protein

1 reference

7 January 2021

A comparison of the biological activities of wild-type and mutant p53.

1 reference

7 January 2021

Analysis of the most representative tumour-derived p53 mutants reveals that changes in protein conformation are not correlated with loss of transactivation or inhibition of cell proliferation.

1 reference

7 January 2021

p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities

1 reference

7 January 2021

p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development

1 reference

7 January 2021

p63 is a p53 homologue required for limb and epidermal morphogenesis

1 reference

7 January 2021

p73 is a simian [correction of human] p53-related protein that can induce apoptosis

1 reference

7 January 2021

A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma

1 reference

7 January 2021

p53 mutations implicate sunlight in post-transplant skin cancer irrespective of human papillomavirus status

1 reference

7 January 2021

p73 function is inhibited by tumor-derived p53 mutants in mammalian cells.

1 reference

7 January 2021

Gain of function mutations in p53.

1 reference

7 January 2021

Different tumor-derived p53 mutants exhibit distinct biological activities

1 reference

7 January 2021

Mutant p53 protein expression interferes with p53-independent apoptotic pathways

1 reference

7 January 2021

Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy

1 reference

7 January 2021

The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage

1 reference

7 January 2021

The polyproline region of p53 is required to activate apoptosis but not growth arrest.

1 reference

7 January 2021

Identification of a novel p53 functional domain that is necessary for efficient growth suppression

1 reference

7 January 2021

Analysis of a germ line polymorphism of the p53 gene in lung cancer patients; discrete results with smoking history.

1 reference

7 January 2021

Determination of the allelic frequencies of an L-myc and a p53 polymorphism in human lung cancer.

1 reference

7 January 2021

Higher lung cancer risk for younger African-Americans with the Pro/Pro p53 genotype.

1 reference

7 January 2021

P53 polymorphisms and haplotypes in lung cancer

1 reference

7 January 2021

Germ line polymorphisms of p53 and CYP1A1 genes involved in human lung cancer

1 reference

7 January 2021

Polymorphism at codon 72 of the p53 gene in human acute myelogenous leukemia

1 reference

7 January 2021

p53 codon 72 polymorphism and risk of cervical cancer in UK.

1 reference

7 January 2021

1 reference

7 January 2021

1 reference

7 January 2021

1 reference

7 January 2021

1 reference

7 January 2021

Is p53 polymorphism maintained by natural selection?

1 reference

7 January 2021

Suppression of human colorectal carcinoma cell growth by wild-type p53

1 reference

7 January 2021

Transcriptional activation by p53 correlates with suppression of growth but not transformation.

1 reference

7 January 2021

Functional domains of wild-type and mutant p53 proteins involved in transcriptional regulation, transdominant inhibition, and transformation suppression

1 reference

7 January 2021

WAF1, a potential mediator of p53 tumor suppression

1 reference

7 January 2021

Mutations in the p53 gene occur in diverse human tumour types

1 reference

7 January 2021

Detection of loss of heterozygosity at the human TP53 locus using a dinucleotide repeat polymorphism

1 reference

7 January 2021